Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells
Breast Cancer Research and Treatment · 2024-01 · 203 (2) · 383-396
DOI: 10.1007/s10549-023-07136-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 17.10.2023. Verfasst von Biao Hu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Michigan, G349B, 520 NCRC, 1600 Huron Parkway, Ann Arbor, MI, 48109, USA. biaohu@med.umich.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: NIDDK NIH HHS, University of Michigan Regional Comprehensive Metabolomics Resource Core.
Abstract (Originalsprache)
PURPOSE: Estrogen Receptor α (ERα) is a well-established therapeutic target for Estrogen Receptor (ER)-positive breast cancers. Both Selective Estrogen Receptor Degraders (SERD) and PROTAC ER degraders are synthetic compounds suppressing the ER activity through the degradation of ER. However, the differences between SERD and PROTAC ER degraders are far from clear. METHODS: The effect of PROTAC ER degrader ERD-148 and SERD fulvestrant on protein degradation was evaluated by western blot analysis. The cell proliferation was tested by WST-8 assays and the gene expressions were assessed by gene microarray and real-time RT-PCR analysis after the compound treatment. RESULTS: ERD-148 is a potent and selective PROTAC ERα degrader. It degrades not only unphosphorylated ERα but also the phosphorylated ERα in the cells. In contrast, the SERD fulvestrant showed much-reduced degradation potency on the phosphorylated ERα. The more complete degradation of ERα by ERD-148 translates into a greater maximum cell growth inhibition. However, ERD-148 and fulvestrant share a similar gene regulation profile except for the variation of regulation potency. Further studies indicate that ERD-148 degrades the ERα in fulvestrant-resistant cells. CONCLUSION: PROTAC ER degrader has a different mechanism of action compared to SERD which may be used in treating fulvestrant-resistant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Michigan, G349B, 520 NCRC, 1600 Huron Parkway, Ann Arbor, MI, 48109, USA. biaohu@med.umich.edu.
- Department of Internal Medicine, University of Michigan, G349B, 520 NCRC, 1600 Huron Parkway, Ann Arbor, MI, 48109, USA.
Förderung
- NIDDK NIH HHS
- University of Michigan Regional Comprehensive Metabolomics Resource Core
Zitieren
APA
Hu, B., & Hu, J. (2024). Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells. Breast Cancer Research and Treatment, 203(2), 383-396. https://doi.org/10.1007/s10549-023-07136-2
Vancouver
Hu B, Hu J. Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells. Breast Cancer Research and Treatment. 2024;203(2):383-396. doi:10.1007/s10549-023-07136-2
BibTeX
@article{Hu2024,
author = {Hu, Biao and Hu, Jiantao},
title = {Complete elimination of estrogen receptor α by PROTAC estrogen receptor α degrader ERD-148 in breast cancer cells},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {203},
number = {2},
pages = {383--396},
doi = {10.1007/s10549-023-07136-2}
}
EUVIMED